Title : Gain-of-Function Mutant TP53 R248Q Overexpressed in Epithelial Ovarian Carcinoma Alters AKT-Dependent Regulation of Intercellular Trafficking in Responses to EGFR/MDM2 Inhibitor.

Pub. Date : 2021 Aug 16

PMID : 34445495






3 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 Previously, we have demonstrated that the combined inhibition of EGFR and MDM2-p53 pathways, by gefitinib and JNJ-26854165, exerts a strong synergistic lethal effect on HGSOC cells. Gefitinib tumor protein p53 Homo sapiens
2 The targeted inhibition responses of gefitinib and JNJ-26854165, in p53R248Q-overexpressing cells, were extensively evaluated. Gefitinib tumor protein p53 Homo sapiens
3 Next, we analyzed the gefitinib and JNJ-26854165 responses and found differential sensitivity to the single- or combined-drug inhibitions in p53R248Q-overexpressing cells. Gefitinib tumor protein p53 Homo sapiens